Literature DB >> 16150802

Alphavbeta3-targeted detection of arteriopathy in transplanted human coronary arteries: an autoradiographic study.

Jiasheng Zhang1, Svetlana Krassilnikova, Amir A Gharaei, Hooman Rastegar Fassaei, Leila Esmailzadeh, Abolfazl Asadi, D Scott Edwards, Thomas D Harris, Michael Azure, George Tellides, Albert J Sinusas, Barry L Zaret, Jeffrey R Bender, Mehran M Sadeghi.   

Abstract

Graft arteriopathy (GA), characterized by diffuse concentric narrowing of coronary arteries, is the major cause of late graft failure in cardiac transplantation. alphavbeta3 Integrin is up-regulated in proliferating vascular cells and may constitute an appropriate target for imaging GA. We used a human/mouse chimeric model of GA, in which segments of human coronary artery were transplanted to severe combined immunodeficiency mice, followed by reconstitution with allogeneic human peripheral blood mononuclear cells (PBMC). This led to vascular remodeling characterized by neointima formation over a period of 4 wk. alphavbeta3 expression in the graft was minimal in animals without PBMC, considerably increased by 2 wk, and decreased toward baseline by 4 wk after PBMC reconstitution. Cell proliferation was maximal at 2 wk, correlating with peak alphavbeta3 expression. RP748, an 111In-labeled alphavbeta3 (active conformation)-targeted radiotracer was injected into groups of 5 recipients at 0, 2, and 4 wk after PBMC reconstitution. Relative uptakes, defined as autoradiographic intensity in the graft/native aortas closely tracked the proliferative process. Specificity of uptake was demonstrated using excess nonlabeled tracer. In conclusion, alphavbeta3 integrin is transiently up-regulated (and activated) in GA and may be targeted by RP748 for detection of the proliferative process in early GA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16150802     DOI: 10.1096/fj.05-4130fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  8 in total

1.  Molecular imaging of vascular endothelial growth factor receptors in graft arteriosclerosis.

Authors:  Jiasheng Zhang; Mahmoud Razavian; Sina Tavakoli; Lei Nie; George Tellides; Joseph M Backer; Marina V Backer; Jeffrey R Bender; Mehran M Sadeghi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-06-21       Impact factor: 8.311

Review 2.  The pathobiology of the vessel wall: implications for imaging.

Authors:  Mehran M Sadeghi
Journal:  J Nucl Cardiol       Date:  2006 May-Jun       Impact factor: 5.952

Review 3.  Molecular cardiovascular imaging using scintigraphic methods.

Authors:  Lars Stegger; Klaus Schäfers; Klaus Kopka; Stefan Wagner; Sven Hermann; Peter Kies; Marilyn Law; Otmar Schober; Michael Schäfers
Journal:  Eur Radiol       Date:  2007-01-06       Impact factor: 5.315

4.  Integrin-targeted imaging of inflammation in vascular remodeling.

Authors:  Mahmoud Razavian; Ravi Marfatia; Heloise Mongue-Din; Sina Tavakoli; Albert J Sinusas; Jiasheng Zhang; Lei Nie; Mehran M Sadeghi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-09-22       Impact factor: 8.311

Review 5.  Imaging atherosclerosis and vulnerable plaque.

Authors:  Mehran M Sadeghi; David K Glover; Gregory M Lanza; Zahi A Fayad; Lynne L Johnson
Journal:  J Nucl Med       Date:  2010-04-15       Impact factor: 10.057

Review 6.  Molecular imaging of coronary atherosclerosis and myocardial infarction: considerations for the bench and perspectives for the clinic.

Authors:  Florian Leuschner; Matthias Nahrendorf
Journal:  Circ Res       Date:  2011-03-04       Impact factor: 17.367

Review 7.  Multimodality cardiovascular molecular imaging, Part II.

Authors:  Matthias Nahrendorf; David E Sosnovik; Brent A French; Filip K Swirski; Frank Bengel; Mehran M Sadeghi; Jonathan R Lindner; Joseph C Wu; Dara L Kraitchman; Zahi A Fayad; Albert J Sinusas
Journal:  Circ Cardiovasc Imaging       Date:  2009-01       Impact factor: 7.792

Review 8.  Evaluation of cardiac allograft vasculopathy by positron emission tomography.

Authors:  Attila Feher; Albert J Sinusas
Journal:  J Nucl Cardiol       Date:  2021-01-03       Impact factor: 5.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.